Posts by Mourabit Halima

The 2024 European Society for Medical Oncology (ESMO) Congress took place in Barcelona, Spain, from September 13 to 17. During the event, Dr. Miaoyan Wei from Fudan University Shanghai Cancer Center presented the results of an open-label, single-arm, single-center Phase II clinical trial exploring the use of fruquintinib combined with nab-paclitaxel and gemcitabine (AG) as a first-line treatment for liver metastases in pancreatic ductal adenocarcinoma (PDAC). This study was featured in the poster session (Abstract #1529P). In this interview, Dr. Wei provides an in-depth analysis of the study's findings.

The 2024 European Society for Medical Oncology (ESMO) Annual Congress was held from September 13 to 17 in Barcelona, Spain, where multiple advancements in lung cancer research were presented. Dr. Jonathan D. Spicer from the McGill University Health Centre in Montreal, Canada, shared the updated clinical data from the CheckMate 77T study. During the congress, Oncology Frontier interviewed Professor Spicer, who provided insights on the updated data and discussed how to choose between neoadjuvant therapy, adjuvant therapy, and perioperative strategies in resectable non-small cell lung cancer (NSCLC).

The 2024 World Conference on Lung Cancer (WCLC) recently concluded in San Diego, USA. As one of the largest academic conferences in the field of oncology, WCLC presents the latest cutting-edge advancements, covering all aspects of lung cancer research. Dr. Yilong Wu from Guangdong Provincial People’s Hospital served as an expert chair and delivered a keynote presentation during an educational session, sharing the results of several clinical trials. Oncology Frontier had the privilege of interviewing Professor Wu onsite, where he reflected on his experience attending the 2024 WCLC.

A patient-level analysis of the phase III CheckMate 77T trial (NCT04025879) and the phase III CheckMate 816 trial (NCT02998528) revealed that perioperative treatment with nivolumab for resectable non-small cell lung cancer (NSCLC) patients reduces the risk of disease recurrence or death by approximately 40%, compared to neoadjuvant nivolumab plus chemotherapy alone. This article presents Dr. Yong Song from General Hospital of Eastern Theater Command’s insights on the analysis results (Abstract PL02.07).

The 2024 World Conference on Lung Cancer (WCLC), taking place from September 7-10 in San Diego, USA, will showcase key findings from Chinese researchers, including a phase III randomized controlled trial comparing plinabulin plus docetaxel versus docetaxel alone for the treatment of advanced non-small cell lung cancer (NSCLC) after progression on platinum-based chemotherapy. The results of this study will be presented during the "OA08 – New Generation of Cytotoxic Agents" session and published in The Lancet Respiratory Medicine on the same day.

During the second Presidential Symposium at the 2024 World Conference on Lung Cancer (WCLC), Professor Jing-Ji Yang from Guangdong Provincial People’s Hospital presented the report “Osimertinib with or without Savolitinib as First-Line Treatment for De Novo MET Aberrant, EGFRm Advanced Non-Small Cell Lung Cancer (NSCLC) (CTONG 2008): Results from the Phase II FLOWERS Clinical Trial.”

The 2024 European Society for Medical Oncology (ESMO) Congress took place from September 13 to 17 in Barcelona, Spain, where significant progress in lung cancer research was unveiled. Dr. Ben J. Solomon, from the Peter MacCallum Cancer Centre in Melbourne, Australia, shared the results of the biomarker analysis from the ALINA study. In an exclusive interview with Oncology Frontier, Professor Solomon discussed the efficacy, safety, and biomarker analysis of alectinib in ALK-positive non-small cell lung cancer (NSCLC) patients. He also highlighted the latest advancements in targeted therapies for ALK-positive and KRAS G12C-mutant NSCLC.

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting has successfully concluded. Several studies presented during the neuroendocrine tumor (NET) oral sessions have offered new treatment strategies and molecular profiling for advanced unresectable NETs. Notably, the Phase III CABINET study on cabozantinib achieved its primary endpoint of progression-free survival (PFS), and the multi-center single-arm CVM-005 study showed impressive PFS results with the anti-vasculogenic mimicry drug CVM-1118, especially when combined with SSA (somatostatin analogs), with the median PFS for extra-pulmonary NETs reaching nearly two years. Furthermore, multi-omics profiling has provided a foundation for prognostic assessment, classification-based treatment, and biomarker exploration in NETs. Oncology Frontier invited Dr. Jie Chen from Fudan University Shanghai Cancer Center to introduce and comment on these studies.